~~<i id='ADA899B0D7'><strike id='ADA899B0D7'><tt id='ADA899B0D7'><pre id='ADA899B0D7'></pre></tt></strike></i>~~

Home» Wikipedia» entertainment

entertainment

author：fashion 2025-09-27 20:51:29 Page View：2261

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Menendez indictment could see pharma lose a key ally
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

explore

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Medicare drug price negotiation program allowed for now

AfederaljudgemadeakeyrulinginalawsuitchallenginganewdrugpricingprogramAdobeWASHINGTON—Afederalcourtj

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Listen: Who gets the credit for GLP

Whenisnegativedatapositiveenough?Whogetscreditforscientificbreakthroughs?Andwasn’tbiotechsupposedtob